Targeting a neoantigen derived from a common TP53 mutation.
Hsiue, E.H., Wright, K.M., Douglass, J., Hwang, M.S., Mog, B.J., Pearlman, A.H., Paul, S., DiNapoli, S.R., Konig, M.F., Wang, Q., Schaefer, A., Miller, M.S., Skora, A.D., Azurmendi, P.A., Murphy, M.B., Liu, Q., Watson, E., Li, Y., Pardoll, D.M., Bettegowda, C., Papadopoulos, N., Kinzler, K.W., Vogelstein, B., Gabelli, S.B., Zhou, S.(2021) Science 371
- PubMed: 33649166 
- DOI: 10.1126/science.abc8697
- Primary Citation of Related Structures:  
6W51 - PubMed Abstract: 
TP53 (tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as TP53 , are not yet available. Here, we describe the identification of an antibody highly specific to the most common TP53 mutation (R175H, in which arginine at position 175 is replaced with histidine) in complex with a common human leukocyte antigen-A (HLA-A) allele on the cell surface ...